Kyle Jenne Sells 1,823 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Kyle Jenne sold 1,823 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $75.96, for a total value of $138,475.08. Following the completion of the transaction, the executive vice president directly owned 16,389 shares of the company’s stock, valued at $1,244,908.44. This trade represents a 10.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ionis Pharmaceuticals Stock Up 2.5%

Shares of NASDAQ:IONS opened at $79.44 on Thursday. The firm has a 50 day simple moving average of $79.03 and a 200-day simple moving average of $64.43. Ionis Pharmaceuticals, Inc. has a twelve month low of $23.95 and a twelve month high of $86.15. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. The company has a market capitalization of $12.87 billion, a PE ratio of -47.01 and a beta of 0.28.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The firm had revenue of $156.72 million for the quarter, compared to analyst estimates of $131.75 million. During the same period last year, the business earned ($0.95) EPS. Ionis Pharmaceuticals’s revenue for the quarter was up 17.2% compared to the same quarter last year. On average, equities analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Key Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Olezarsen thesis: Analysts and media highlight an expected 2026 launch of olezarsen in severe hypertriglyceridemia (SHTG). The piece argues commercial approval/rollout could drive a substantial revenue inflection and is cited as the primary bullish catalyst for IONS. Read More.
• Neutral Sentiment: Analyst coverage: Several firms have raised targets or maintained positive ratings (examples: Leerink raised its target, Raymond James reaffirmed “strong-buy”); consensus remains a Moderate Buy with a target around ~$87. These upgrades underpin optimistic expectations but are not a guarantee of near‑term moves. Read More.
• Neutral Sentiment: Technical / flows: Intraday volume is well above typical averages and the shares sit above the 200‑day moving average but near the 50‑day—momentum may hinge on clinical/commercial milestones and further news on olezarsen.
• Negative Sentiment: Concentrated insider selling: Multiple senior executives, including CEO Brett Monia and several EVPs, disclosed large open‑market sales on Jan. 16 (aggregate roughly ~117k shares / several million dollars), reducing their holdings by double‑digit percentages in some cases. Such high‑profile selling can weigh on sentiment even if it reflects diversification or tax planning. Read More. • Read More.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on IONS shares. Stifel Nicolaus raised their target price on shares of Ionis Pharmaceuticals from $43.00 to $67.00 and gave the stock a “hold” rating in a research report on Monday, October 6th. Raymond James Financial reiterated a “strong-buy” rating and issued a $89.00 price objective (up previously from $85.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, October 30th. The Goldman Sachs Group upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “neutral” rating and lifted their price target for the company from $45.00 to $65.00 in a research report on Friday, September 26th. Leerink Partners raised their price objective on Ionis Pharmaceuticals from $85.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Finally, Oppenheimer boosted their target price on Ionis Pharmaceuticals from $84.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.45.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Steigerwald Gordon & Koch Inc. purchased a new stake in Ionis Pharmaceuticals during the 3rd quarter worth about $25,000. Golden State Wealth Management LLC lifted its holdings in Ionis Pharmaceuticals by 198.4% in the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after purchasing an additional 250 shares in the last quarter. Mather Group LLC. acquired a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth about $27,000. Allworth Financial LP boosted its stake in shares of Ionis Pharmaceuticals by 231.8% during the 2nd quarter. Allworth Financial LP now owns 740 shares of the company’s stock worth $29,000 after purchasing an additional 517 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter worth about $38,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.